DOCMEDIUM SIGNALFINANCIAL10-K

DOC experienced a substantial decline in net income while increasing debt levels and reducing share buybacks, suggesting financial performance pressures despite maintaining positive operating cash flow growth.

The company's profitability was meaningfully reduced year-over-year while debt increased by $1.1 billion, indicating either acquisition activity or refinancing needs that may be pressuring returns. The reduction in share buyback activity alongside declining stockholders' equity suggests management is prioritizing capital preservation over shareholder returns in the current environment.

Comparing 2026-02-03 vs 2025-02-04View on EDGAR →
FINANCIAL ANALYSIS

DOC's financial profile shows mixed signals with operating cash flow growing modestly to $1.3 billion, demonstrating solid operational performance. However, net income declined substantially while total debt increased 13% to $9.8 billion and stockholders' equity contracted to $7.5 billion. The company also reduced share buyback activity by roughly half to $97.1 million, suggesting a more conservative capital allocation approach amid the challenging profitability environment.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-70.7%
$243.1M$71.3M

Net income declined 70.7% — review whether driven by operations, interest costs, or non-recurring items.

Share Buybacks
Cash Flow
-49.1%
$190.7M$97.1M

Buyback activity reduced 49.1% — capital being redeployed elsewhere or cash conservation underway.

Operating Cash Flow
Cash Flow
+17%
$1.1B$1.3B

Operating cash flow grew 17% — strong conversion of earnings to cash, healthy business fundamentals.

Total Debt
Balance Sheet
+13%
$8.7B$9.8B

Debt rose 13% — additional borrowing for investment or operations; monitor coverage ratios.

Stockholders Equity
Balance Sheet
-10.7%
$8.4B$7.5B

Equity decreased 10.7% — buybacks or losses reducing book value, monitor solvency ratios.

Total Liabilities
Balance Sheet
+10.6%
$10.9B$12.0B

Liabilities increased 10.6% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-02-03
PRIOR — 2025-02-04
ADDED
As of January 30, 2026, there were 695,043,997 shares of the registrant s $1.00 par value common stock outstanding.
As more fully set forth under Item 1A, Risk Factors in this report, principal risks and uncertainties that may affect our business, financial condition, or results of operations include: changes to regulatory, funding, staffing, trade, and other policies and actions by the U.S.
The information disclosed through those channels may be considered to be material, so investors should monitor them in addition to our press releases, Securities and Exchange Commission ( SEC ) filings, and public conference calls and webcasts.
We have a diversified portfolio of high-quality healthcare properties across three core asset classes of outpatient medical, lab, and senior housing real estate.
Under the senior housing segment, our properties are operated through RIDEA structures.
+7 more — sign up free →
REMOVED
As of January 31, 2025, there were 699,564,637 shares of the registrant s $1.00 par value common stock outstanding.
In 2023, we completed our corporate reorganization (the Reorganization ) into an umbrella partnership REIT ( UPREIT ).
We have a diversified portfolio of high-quality healthcare properties across three core asset classes of outpatient medical, lab, and continuing care retirement community ( CCRC ) real estate.
Under the CCRC segment, our properties are operated through RIDEA structures.
We have other non-reportable segments that are comprised primarily of: (i) an interest in an unconsolidated joint venture that owns 19 senior housing assets (our SWF SH JV ) and (ii) loans receivable.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →